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1. Introduction 
1.1 Fluoroquinolones in tuberculosis treatment 
Fluoroquinolones are key antibiotics for the second-line treatment of multidrug-resistant 
tuberculosis (MDR-TB), i.e. resistant to the two most powerful antituberculous drugs 
currently available, isoniazid and rifampicin (WHO, 2001; 2011). Unfortunately, extensively 
drug resistant strains (XDR-TB), defined as MDR-TB with bacillary resistant to any 
fluoroquinolones and to one of the three injectable second line anti-TB drugs (amikacin, 
kanamycin or capreomycin), are emerging worldwide (Center for Disease Control and 
Prevention, 2006). XDR-TB strains constitute a major concern for public health since they are 
virtually untreatable and responsible for up to 100% of deaths. Besides being increasingly 
popular in treatment of tuberculosis complicated by intolerance or by relative 
contraindication for first-line drugs, fluoroquinolones are under studies to shorten the 
duration of treatment or replace first line drugs in susceptible tuberculosis. Newer 
fluoroquinolones such as moxifloxacin have already demonstrated potential for shortening 
treatment duration (Rustomjee et al., 2008; Conde et al., 2009; Dorman et al., 2009). 
Fluoroquinolones are also one of the most widely prescribed antibiotics as they are 
generally well tolerated with high oral bioavailability plus broad-spectrum antibacterial 
activities against genitourinary infections and against common respiratory tract pathogens. 
Structurally, these drugs contain a quinoline ring system and hence are given the name 
quinolones (Fig. 1). After the first generation of drugs were found to be active, it was noted 
that a fluorine atom at the 6-position of the quinoline ring imparted greater potency, and 
hence the second generation of drugs was called the fluoroquinolones (Fig. 1). 
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Fig. 1. Chemical structures of a fluoroquinolone (left) and moxifloxacin (right). The fluorine 
atom, signature of fluoroquinolones, is at position 6 in the quinoline ring. In the 
moxifloxacin structure, oxygen atoms are coloured in red, nitrogen atoms in blue, hydrogen 
atoms in green and the fluor atom in purple. R1 is a cyclopropyl group, R5 is a hydrogen 
atom, R7 is an azabicyclo group and X8 a methyl ether group. 
2. Bacterial type II topoisomerases are the target of fluoroquinolones 
Topoisomerases are ubiquitous nucleic acid-dependant nanomachines essential to cell life 
and solve the topological problems of DNA that occur as a result of DNA manipulations 
during replication, transcription, recombination, chromosome segregation and 
condensation, maintenance of nuclear architecture and apoptosis (Champoux, 2001). They 
have been divided into two classes, type I and type II, according to their basic mechanism of 
action (Champoux, 2001; Forterre et al., 2007). Type I DNA topoisomerases introduce 
transient single-stranded breaks to force the passage of one DNA strand through the other, 
whereas type II DNA topoisomerases introduce transient double-stranded breaks to force 
the passage of a second DNA duplex through this broken duplex. All organisms contain at 
least one type I and one type II topoisomerases. Type I and type II topoisomerases can 
sometimes perform similar function in vivo, for example efficient separation of interlocked 
chromosomes at the end of DNA replication via their decatenation activity (Nurse et al., 
2003). All type II topoisomerases can also relax both positive and negative superturns that 
accumulate during transcription and replication. Topoisomerases thus play an essential role 
for the preservation of genome stability in all life forms (Forterre et al., 2007). 
Type II topoisomerases have been further sub-classified into two families, type IIA and IIB, 
based on evolutionary considerations (Champoux, 2001; Forterre et al., 2007). The type IIA 
includes bacterial DNA gyrase and topoisomerase IV, eukaryal and viral topoisomerases, 
whereas the type IIB includes archaeal topoisomerase VI, and their homologues in plants, a 
few protists, and a few bacteria (Forterre et al., 2007; Forterre & Gadelle, 2009). Type IIA and 
IIB topoisomerases are both formed by the association of two subunits, sharing homologous 
sequences and domain organization (Fig. 2). Bacterial type II topoisomerases, DNA gyrase 
and topoisomerase IV, consist of two subunits, GyrA or ParC and GyrB or ParE, which form 
the catalytic active heterotetrameric (A2B2/C2E2) complex. Subunit A consists of two 
domains, the N-terminal breakage-reunion domain and a carboxy-terminal domain, termed 
BRD and CTD, respectively (represented in blue and green respectively in Fig. 2 and 3). 
Subunit B consists of the ATPase domain followed by the Toprim domain (represented in 
yellow and red, respectively, in Fig. 2 and Fig. 3). The GyrB Toprim domain and GyrA BRD 
come from separate subunits and cooperatively form the enzyme catalytic core (see section 
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5). The BRD contains the catalytic tyrosine responsible for the cleavage and religation of the 
DNA double helix.  
 
Fig. 2. Schematic representation of the sequence and domain organization of type II 
topoisomerases found in eukaryotes, bacteria, virus and archaea. The type IIA 
topoisomerase family includes bacterial DNA gyrase and topoisomerase IV (Topo IV), 
eucaryal and viral topoisomerases (Topo II), whereas the type IIB topoisomerase family 
includes archaeal topoisomerase VI (Topo VI), and their homologues in plants and a few 
protists and bacteria. Topo IIA and Topo IIB are both formed by the association of two 
subunits A and B. Bacterial type IIA and type IIB topoisomerases are A2B2 heterotetramers, 
whereas the eukaryotic Topo II is a heterodimer, with the A and B subunits fused in a single 
polypeptide (Nter-B-A-Cter). The names of the four conserved domains are indicated. The 
winged helix domain (WHD) in the type IIB topoisomerase corresponds to the breakage-
reunion domain (BRD) of type IIA topoisomerase. 
Crystallographic studies of individual domains show that the structure of the BRD is a 
heart-shaped arrangement with two dimer interfaces (Morais-Cabral et al., 1997), that the 
CTD displays a spiral six-bladed β-pinwheel structure (Corbett et al., 2004) and that the 
ATPase domain belongs to the GHKL ATPases, a broad family of enzymes with a common 
fold unrelated to other canonical ATP-binding folds (Brino et al., 2000) (Fig. 3). The Toprim 
domain interacts with the A subunit, possesses a magnesium-binding site and is essential 
for DNA binding (Fig. 3). Although no structure for a fully intact active type IIA 
topoisomerase has been determined yet, combination of structural and biochemical studies 
of the individual domains has lead several authors to propose a global quaternary structure 
model and a catalytic mechanism of the holoenzyme (Schoeffler & Berger, 2008). The BRD 
binds a DNA segment termed the ‘gate-’ or G-segment at the DNA-gate (Fig. 3). The  
N-terminal ATPase domains dimerize upon ATP binding, capturing the DNA duplex to be 
transported (T-segment). The T-segment is then passed through a transient break in the  
G-segment opened by the breakage-reunion domains, the DNA is resealed and the T-
segment released through a protein gate, the C-gate, prior to resetting of the enzyme to the 
open clamp form (Fig. 3). 
Quinolones, which target the two bacterial type II topoisomerases, exert their powerful 
antibacterial activity by interfering with the enzymatic reaction cycle. Specifically, they bind 
to the enzyme-DNA binary complex, thereby stabilizing the covalent enzyme tyrosyl-DNA 
phosphate ester (see also section 6 and Fig. 7). The resulting ternary complexes block DNA 
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replication and lead to cell death (Hooper, 2003). In addition, hydrolysis of this linkage leads 
to the accumulation of double-stranded DNA fragments, which accounts for the bactericidal 
activity. 
 
Fig. 3. Crystal structures of the individual domains of type II topoisomerases, as defined in 
Fig. 1. Structures of the GHKL domain (A), Toprim (B), BRD (C) and DNA gyrase CTD (D) 
domains. Two ATP molecules are represented in red in (A). (E) Global architecture of type 
IIA topoisomerases proposed based on the structures of the isolated domains adapted from 
Corbett & Berger (2004). Color code is the same than in Fig. 1. The dimerization interfaces of 
the heterotretramer constitute the three gates (N-, DNA- and C-gate), through which the 
DNA double helix (T-segment, represented in cyan) will be transported. The G-segment that 
binds the DNA-gate is represented in orange. 
3. M. tuberculosis DNA gyrase as the sole target of fluoroquinolones 
Bacterial genomes usually encode two type IIA enzymes, DNA gyrase and topoisomerase 
IV, that together help manage chromosome integrity and topology (Champoux, 2001). DNA 
gyrase is unique in introducing negative supercoils into DNA, an activity mediated by the 
CTD of its DNA binding subunit (GyrA) and is therefore responsible for the DNA 
unwinding at replication forks. Although closely related to DNA gyrase, topoisomerase IV 
has a specialized function in mediating the decatenation of interlocked daughter 
chromosomes (Levine et al., 1998) and relaxes positive supercoils. Particularly intriguing is 
that some bacteria possess in their genome only one type II topoisomerase, DNA gyrase.  
Given the important role of DNA supercoiling in DNA replication, transcription, and 
chromosome dynamics, it is not surprising that DNA gyrase genes have been found in all 
bacterial genomes sequenced to date. In contrast, the topoisomerase IV gene is absent in a 
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few bacteria such as Treponema pallidum, Helicobacter pylori, and notably Mycobacterium 
tuberculosis, the intracellular pathogen that causes tuberculosis (Cole et al., 1998) (Fig. 4). 
Consequently, these bacteria are unusual in producing a “single” type II topoisomerase. 
DNA gyrase is therefore the unique target of fluoroquinolones in these organisms, as it has 
been demonstrated for M. tuberculosis (Mdluli & Ma, 2007).  
 
Fig. 4. Bacterial phylogenetic tree showing the distribution of species known to possess only 
one type II topoisomerase gene in their genome. 
The direct consequence of the presence of a unique type II topoisomerase in M. tuberculosis 
has been investigated and it has been shown that M. tuberculosis DNA gyrase presents two 
specificities. First, this enzyme possesses an “hybrid activity”. In addition to its normal 
supercoiling activity (e.g. comparable to that of E. coli DNA gyrase), it possesses a 
decatenation activity superior to that of DNA gyrase from species harboring two type II 
topoisomerases (Aubry et al., 2006). In addition, it shows an enhanced DNA relaxation and 
cleavage activities. However, the unique type II topoisomerase of M. tuberculosis decatenates 
kDNA less efficiently than a genuine topoisomerase IV, e.g., that of S. pneumoniae. The 
second specificity concerns the susceptibility to fluoroquinolones. The M. tuberculosis DNA 
gyrase is indeed naturally less susceptible to fluoroquinolones than other bacterial DNA 
gyrases. We have shown that three residues of the M. tuberculosis sequence play an 
important role in this natural resistance mechanism (Matrat et al., 2006). Replacing M74 in 
GyrA, A83 in GyrA, and R447 in GyrB of M. tuberculosis gyrase by their E. coli homologs (Ile, 
Ser and Lys, respectively, see residues pink underlined in Fig. 5) resulted in active enzymes 
as quinolone susceptible as the E. coli DNA gyrase. However, the question whether the  
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Fig. 5. Two parts of the multiple alignment of subunit A and B, respectively, centred on the 
quinolone resistance determining regions (QRDR, see section 4 for definition), after Matrat 
et al. (2008). Residues highlighted in blue underline the most important residues shown to 
be involved in acquired resistance to fluoroquinolones. Residues highlighted in pink 
underline residues of the M. tuberculosis DNA gyrase sequence involved in the natural 
resistance mechanism. The numbering at the top of the alignments corresponds to the E. coli 
DNA gyrase numbering. The values of MIC50 and IC50 are given for ofloxacin when known. 
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“single” DNA gyrases of Treponema pallidum or Helicobacter pylori display similar 
specificities, like increased decatenation activity or lower susceptibility to quinolones, is still 
open. 
4. The quinolone resistance determining regions and the quinolone binding 
pocket 
Bacterial resistance to antibiotics typically involves drug inactivation or modification, target 
alteration, or decrease in drug accumulation associated with decrease in permeability and 
increase in efflux (Li & Nikaido, 2004). Fluoroquinolone resistance mechanisms can involve 
two of these three mechanisms, target alterations and overexpression of intrinsic multidrug 
resistance (MDR) efflux pumps (Hooper, 2002). However, resistance to fluoroquinolone is 
mainly due to target modification, e.g. mutations in the DNA gyrase and/or topoisomerase 
IV genes. Mutations conferring bacterial resistance to quinolones occur in two short discrete 
segments termed the quinolone resistance-determining regions (QRDR) in the breakage-
reunion domain of subunit A (QRDR-A) and more rarely in the Toprim domain of subunit B 
(QRDR-B) (Hooper, 1999) (Fig. 6). 
 
Fig. 6. Schematic representation of the M. tuberculosis DNA gyrase sequence. Subunit A 
contains the breakage-reunion domain (BRD, blue) and the C-terminal domain (CTD, 
green). The subunit B contains the ATPase domain (yellow) and the Toprim domain (red). 
Localization of the QRDR is indicated in pink and light blue. The color code is the same than 
in Fig. 2 and 3. The approximate lengths of the QRDRs are indicated (30 and 40 aa for the 
QRDR-A and -B, respectively). The residue ranges of the QRDR-A and -B are indicated for 
the M. tuberculosis and the E. coli DNA gyrase sequences. 
Whereas residues of the QRDR-A have been known for a while that they are spatially close 
to the catalytic tyrosine responsible for the double-stranded DNA cleavage, residues of the 
QRDR-B were only hypothetically thought to be involved in the quinolone-binding pocket 
(Heddle & Maxwell, 2002). This ambiguity was brought about by the two first structures of 
the catalytic core (an homodimer formed by two single polypeptides composed of the 
Toprim domain and the BRD) of the yeast topoisomerase II (Fass et al., 1999; Berger & 
Gamblin, 1996). In these structures, which correspond to two different conformational 
arrangements of the catalytic core, the two QRDRs are too far from each other to form a 
unique binding pocket for the quinolone molecule (Fig. 7).  
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Fig. 7. Side view (top left and right) and top view (bottom left and right) of the catalytic core 
of the yeast topoisomerase II, composed of the Toprim domain (represented in red) and the 
breakage-reunion domain (BRD, represented in blue). (Left) “Open” conformation of the 
catalytic core (PDB code 1BGW, Berger et al., 1996). The DNA-gate is open and the C-gate is 
closed (for definition of DNA- and C-gate, see Fig. 3). The QRDR-B (represented in cyan) are 
close together but distant from the QRDR-A (represented in purple). The QRDR-A includes 
the two DNA-binding helices, H3 and H4. (Right) “Intermediate” conformation of the 
catalytic core (PDB code 1BJT, Fass et al., 1999). The DNA-gate is slightly open and the C-
gate is closed. The QRDR-B are more distant from each other and are closer to the QRDR-A, 
but still do not form a unique quinolone-binding pocket.  
Involvement of QRDR-B residues in the quinolone-binding pocket was definitely confirmed 
in 2009 with the first structure of the S. pneumoniae topoisomerase IV Toprim and breakage-
reunion domains in complex with DNA and moxifloxacin (Lapogonov et al., 2009). This 
structure highlighted the fact that the GyrA BRD and the GyrB-Toprim domain form the 
catalytic core complex, where the double-stranded DNA interacts at the interface of the two 
domains (Fig. 8). This structure brought for the first time the structural evidence of the 
covalent link formed between the DNA and the enzyme, a phosphodiester bond between 
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the oxygen of the tyrosine and the phosphor atom of a phosphate group (Fig. 8). In addition, 
this structure also confirmed that the QRDR-A corresponds to the DNA-binding domain of 
the subunit A often referred to as a CAP-like domain constituted by a helix-turn-helix motif 
(H3 and H4). The QRDR-B corresponds to the DNA-binding region of subunit B that 
involves a helix and a long loop (see section 5). However, the main conclusion of this work 
was that the conformational arrangement observed in this structure brings together the two 
QRDRs to form a unique quinolone-binding pocket (see section 6) at the interface formed by 
the DNA, the BRD and the Toprim domain (Fig. 8). 
 
Fig. 8. Crystal structure of the S. pneumoniae topoisomerase IV catalytic core that comprises 
the GyrB Toprim domain and GyrA BRD in complex with DNA and moxifloxacin. The 
Toprim domain is represented in red, the BRD in blue, the 35 base pairs DNA 
oligonucleotide in orange and the moxifloxacin in green. (Top) Side and top views of the 
molecular surface of the catalytic core. (Bottom) Close view of the catalytic tyrosine 
(represented in blue sticks) before and after formation of the covalent link between the 
enzyme and DNA (the phosphodiester bond is indicated by a black arrow). Residues of the 
Toprim domain chelating the magnesium ion are represented in red sticks.  
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5. Structural studies of the M. tuberculosis DNA gyrase catalytic core 
We recently solved the crystal structures of two domains of the M. tuberculosis DNA gyrase, 
the GyrB Toprim (TopBK) and the GyrA breakage-reunion (GA57BK) domains (Piton et al., 
2009; 2010). These two domains form the DNA gyrase catalytic core that corresponds to the 
smallest entity able to catalyse DNA cleavage (Piton et al., 2010). 
We solved two high resolution structures of the Toprim domain to 2.1 and 1.95 Å resolution, 
respectively. These two structures display two different conformations of the magnesium 
binding site. The QRDR-B is constituted by residues 500 to 538 (461-499 in the PDB 
numbering). Part of this region is disordered and corresponds to a loop that has been named 
DNA-binding loop (DBL) because it is folded in the presence of DNA (Fig. 9). We obtained 
four crystal forms of the breakage-reunion domain, diffracting from 4.2 to 2.7 Å resolution 
depending on the crystal form (Piton et al., 2009). This was the first structure determination 
report of the BRD of a DNA gyrase from a species containing one unique type II 
topoisomerase. The structure of this domain is unexpectedly very similar to other structures 
of BRD solved for bacterial type II topoisomerases, DNA gyrase and topoisomerase IV 
(Morais-Cabral et al., 1997; Carr et al., 2007). It displays the typical heart-like shaped 
structure with a hole of 30 Å diameter at the center allowing the passage of the DNA from 
the DNA-gate to the C-gate (Fig. 9). The QRDR-A is localised at the DNA-gate (shown in 
purple in Fig. 9).  
 
Fig. 9. Crystals (top) and crystal structures (down) of the GyrB Toprim (TopBK, PDB code 
3IG0, 242 residues) domain represented in red (left) and the GyrA breakage-reunion (BRD, 
GA57BK, PDB code 3IFZ, 508 residues per monomer) represented in blue (right). The 
QRDR-B is represented in cyan in the TopBK structure (residues 500-538), the QRDR-A is 
represented in purple in the GA57BK structure (residues 74-101). 
Using the two crystal structures we determined, the GyrA BRD (GA57BK) and the GyrB 
Toprim (TopBK) domains, we performed the modeling of the M. tuberculosis catalytic core in 
complex with a 35 base pairs DNA oligonucleotide and the most used fluoroquinolone, 
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moxifloxacin. In both the crystal structure of the S. pneumoniae topoisomerase IV and the 
modeled M. tuberculosis DNA gyrase catalytic cores, the fluoroquinolone molecules are 
bound at the ternary interface formed by the DNA, the BRD and the Toprim domain (Fig. 8 
and 10). The general mode of action known for quinolones, common to DNA gyrase and 
topoisomerase IV, was the inhibition of the broken DNA religation. The way how these 
molecules are responsible for this inhibition has been clarified by the structure. Whereas 
quinolones are not DNA intercalators, the fluoroquinolone molecule is intercalated in the 
ternary complex between the dinucleotide step where the covalent bond between the DNA 
and the enzyme (with the catalytic tyrosine) is formed (Fig. 8 and 10). As the catalytic core is 
dimeric, two fluoroquinolones molecules are bound spaced by four base pairs (Fig. 10). The 
consequence of this intercalation is that the O3’-P religation is structurally impossible 
because both atoms are too far away from each other (more than 9 Å) (Fig. 10).  
 
Fig. 10. Structure of the M. tuberculosis DNA gyrase catalytic core in complex with DNA and 
moxifloxacin. Side view (top left) and top view (top right) of the molecular surface of the 
catalytic core. The Toprim domain is represented in red, the BRD in blue, the 35 base pairs 
DNA oligonucleotide in orange and the moxifloxacin in green. (Bottom left) Close view of 
the structure of the intercalated moxifloxacin (magenta) in the broken DNA double helix 
(green). The catalytic tyrosine (Y129 in the M. tuberculosis DNA gyrase sequence) is shown in 
green outside the DNA helix. (Bottom right) Close view of both moxifloxacin molecules in 
the broken DNA showing the four base pairs in between the two bound fluoroquinolones. 
Both catalytic tyrosines of each monomer are shown in green in the DNA major groove. 
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6. Fluoroquinolone resistance in M. tuberculosis 
Fluoroquinolone resistance in M. tuberculosis is defined by resistance to ofloxacin (ability of 
the bacilli to grow on medium containing 2 mg/l ofloxacin (WHO, 2001) and is mainly due 
to mutations in DNA gyrase in the QRDRs (see section 4) (Takiff et al., 1994). Mutations 
within the QRDRs are responsible of at least 75% of fluoroquinolone resistance in 
M. tuberculosis, affecting most commonly the GyrA subunit (G88A, A90V, S91P, D94G, H, N, 
Y) but also the GyrB subunit (Aubry et al., 2006b; Veziris et al., 2007; Siddiqi et al., 2002; 
Feuerriegel et al., 2009). Modeling of the M. tuberculosis DNA gyrase catalytic core allowed 
to clearly establish that QRDR residues of both subunits are spatially close and form the 
quinolone-binding pocket (QBP) (Fig. 11). In this pocket, the fluoroquinolone is maintained 
on one side by three residues of the QRDR-A, G88, D89 and A90, that are in close contact 
with the quinolone conserved carboxylic function (R3 group, Fig. 1 and 11), and on the other 
side by five residues of the QRDR-B, D500, R521, N538, T539 and E540 in close contact with 
the R1, R7 and R8 groups of the quinolone (Fig. 1 and 11). Almost all these residues have 
been shown to be directly involved in the level of resistance to fluoroquinolone when they 
are modified (Aubry et al., 2004; 2006; Matrat et al., 2006; 2008; Mokrousov et al., 2008; Von  
Groll et al., 2009; Kim et al., 2011). The model shows that the geometry of the QBP is crucial 
for the recognition and the stability of fluoroquinolone in the pocket. Any modification of 
the amino acids belonging to the QBP leads to either a direct or indirect change of the 
geometry of the pocket (Fig. 11). The pocket becomes too large to stabilize the 
fluoroquinolone, when the side chain of the modified amino acid becomes smaller. In 
contrast, the pocket becomes too small to fix the fluoroquinolone, when the side chain of the 
modified amino acid is bulkier. An indirect effect on the geometry of the pocket is observed 
when amino acid substitutions are localised in the H4 helix that interacts with the major 
groove of the DNA. As DNA is also part of the QBP (Fig. 11), modification of the structure  
of the DNA will modify the geometry of the pocket, and can lead to destabilisation of the 
fluoroquinolones in the pocket. This mechanism could explain why substitutions of the 
amino acid D94 (position mostly found in M. tuberculosis strains resistant to quinolones) 
have paradoxical effects, e.g. the substitution by an amino acid with a smaller side chain, 
such as alanine or glycine, increases the resistance to the same level than the substitutions by 
amino acids with bulky side chains. 
Resistance to fluoroquinolones of M. tuberculosis DNA gyrase results from two mechanisms. 
On one hand, the lower natural affinity of the M. tuberculosis DNA gyrase catalytic core for 
fluoroquinolones is responsible for “intrinsic resistance” and is attributable to the amino 
acid nature at three positions, 81 and 90 in the QRDR-A and 521 in the QRDR-B (see section 
3). On the other hand, DNA gyrase modifications found in the QRDRs of DNA gyrases of 
clinical M. tuberculosis strains are responsible for “acquired resistance”. Interestingly, amino 
acid at two positions in the QBP play a crucial role in both natural and acquired resistance, 
position 90 in the QRDR-A, which is an alanine in the M. tuberculosis sequence and position 
521, an arginine in the M. tuberculosis QRDR-B. Both amino acid are essential for the shape of 
the QBP and, as a result, for the binding of quinolone. For example, the substitution of 
residue A90 in the wild-type M. tuberculosis DNA gyrase to S90 generates a pocket better 
adapted to the size of moxifloxacin (Fig. 12), increasing the susceptibility to this inhibitor. In 
contrast, the A90V substitution, found in some strains resistant to moxifloxacin, generates a 
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pocket too small to bind moxifloxacin (Fig. 12). In the QRDR-B, the side chain of residue 
R521, an amino acid located in the Toprim DBL, points towards the DNA minor groove and 
forms a “flap” that blocks the fluoroquinolone in the pocket through contact with the R7 
group (Fig. 11). The increase of susceptibility to fluoroquinolones by the substitution of R521 
to lysine can be explained by the lower energy cost when moving an arginine than a lysine 
in the DNA minor groove (Rohs et al., 2010). This means that the “flap” created by this 
amino acid, would find it easier to open up and destabilize the fluoroquinolone, when this 
residue is an arginine rather than a lysine. 
 
Fig. 11. (Top) Schematic representation of the M. tuberculosis DNA gyrase sequence. Subunit 
A contains the breakage-reunion domain (BRD, blue) and the C-terminal domain (CTD, 
green). The subunit B contains the ATPase domain (yellow) and the Toprim domain (red). 
End of legend. Localization of the QRDR is indicated in pink and light blue. (Bottom left) Top 
view of the molecular surface representation of the M. tuberculosis DNA gyrase catalytic core 
in complex with DNA and moxifloxacin showing the QBP (color code is the same than in 
Fig. 10). The QRDR-A and -B are represented in pink and light blue, respectively. (Right) 
Close view of the quinolone-binding pocket. The DNA-protein complex is represented in 
transparent molecular surface and moxifloxacin in sticks (color code is the same than in Fig. 
10). The residues of the QRDR-B (Toprim) belonging to the QBP are indicated in pink, 
purple and yellow. Resides A90 of the QRDR-B is represented in light green in the 
background of the pocket. 
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Fig. 12. Effect of the substitution of A90 (QRDR-A) on the geometry of the quinolone-
binding pocket. (Left) Quinolone-binding pocket of the wild-type M. tuberculosis DNA 
gyrase. The A90 is coloured in yellow. (Middle) Substitution of A90 to serine (S90 is 
represented in green). (Right) Substitution of A90 to valine (V90 is represented in magenta). 
7. Conclusion 
This chapter has described the structural insights into the bacterial type II topoisomerases, 
the targets of quinolones and into the quinolone resistance mechanism, discussed in the 
context of the enzyme modifications, e.g. amino acid substitutions, described in the 
literature that are implicated in quinolone resistance. It has shown that the tridimensional 
structure of the M. tuberculosis catalytic core in complex with DNA and a quinolone 
molecule is a powerful tool to better understand the relationships between the sequence, the 
structure and the resistance phenotype in M. tuberculosis DNA gyrase. 
Knowledge of structural data has applications both in the diagnosis of resistance in 
M. tuberculosis but also in tuberculosis treatment. This powerfulness consists in four 
essential aspects. It strongly contributes to (1) the analyses of the results obtained by 
molecular studies since the variety of new mutations, especially in the GyrB subunit, is 
increasing, (2) the discrimination between substitutions identified in fluoroquinolone-
resistant clinical strains that are implicated or not in fluoroquinolone resistance (Pantel et al., 
2011), (3) the prediction of the effect on susceptibility to quinolones of new undescribed 
mutations, and finally (4) to the design of new quinolones, as  quinolones used nowadays 
for tuberculosis treatment have been designed before structural data on the M. tuberculosis 
DNA gyrase catalytic core were available. 
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